Summary
This study will compare the clinical activity of novel regimens (in combination or as single
agents) to SoC in participants with relapsed/refractory advanced NSCLC. The study will be
conducted in two parts. Part 1 is an open-label, optional, non-randomized part based on
safety and pharmacokinetics/pharmacodynamics (PK/PD) evaluation intended to generate
additional data to qualify novel regimens for the randomized study. Part 2 is a randomized,
Phase II open-label part comparing the efficacy and safety of these novel regimens with SoC.
Drug name mentioned as GSK4428859A (belrestotug) and EOS884448 are interchangeable for the
same compound and will be referred to as GSK4428859A/EOS884448/belrestotug.